Supplementary Figure S1: FGFR4 silencing synergistically enhances the effects of chemotherapy in colon cancer cells. siFGFR4 FGFR4_6 FGFR4_2 Neg Con FGFR4.

Slides:

Advertisements

Similar presentations

Supplementary Figure 1. Caspase 8 expression and activation and Fas expression in NSCLC and normal lung cell lines. A Western blot analysis of DR4 and.

Advertisements

ABAB p53 caffeine doxo h 48h Casp8 Casp10 FADD FLIP Bcl-2 BIM BID PUMA Bax Bak XIAP cIAP-1 cIAP-2 GAPDH MFI untreated 3,3x10 3 MFI doxo.

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

H1299 Vector H1648 TUSC2 TUSC2 -ER 2.3 uM ER H1299 Vector TUSC2 TUSC2 -ER 2.3 uM ER H1299 Vector H1648 TUSC2 TUSC2 -ER 2.3 uM ER H1299 Vector TUSC2 TUSC2.

Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.

ShCon shNaa10p GAPDH MCL1 EPHB4 RPS6KA5 SMAD1 BFAR EIF4B CYR61 STAT5B NFkbil2 VEGFC TNFRSF1A CyclinD Supplementary Figure S1 RKO cells A B siCon siNaa10p-395siNaa10p-464siNaa10p-649.

Supplementary Figures NormalCRC CRC+5FU CRC+CPT11 100µm S1.

Supplementary Figure 1 Supplementary Figure 1. Representative micrographs of migration and invasion assays. miR-452 or si-WWP1 transfectants inhibited.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Wu et al., Supplementary Fig 1 Supplementary Figure 1: The depletion of BRG1 in HeLa cells has no effect on cell proliferation. Sh- empty vector was used.

Supplementary Figure S1 a

Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,

Supplementary Figure 1. Importance of first neighbours in breast cancer, hepatocellular carcinoma and non-small cell lung cancer in the SignaLink network.

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

From: Lentiviral Vector-Mediated PAX6 Overexpression Promotes Growth and Inhibits Apoptosis of Human Retinoblastoma Cells Invest. Ophthalmol. Vis. Sci..

Products > DLD-1 Transfection Reagent (Colon Cancer, CCL-221)

Figure S2 apoptosis-PARP -WB

Supplementary Figure 1 (log fold change relative to untreated control)

Chemotherapy and Cancer Stem Cells

Volume 26, Issue 2, Pages (August 2014)

A B C Supplementary figure S7

Supplementary figure S1 by Shin et al.

Supplementary Figure 1 A B catalase p53 catalase MW(kDa) PIG3 MW(kDa)

Red: stable co-clustering Blue: no co-clustering

Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

A B HT29 HCT15 Colo205 Ls174T LS180 Isotypic control

Exploiting the Hidden Treasure of Detained Introns

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

Marissa V. Powers, Paul A. Clarke, Paul Workman Cancer Cell

I. Kausch, H. Jiang, B. Thode, C. Doehn, S. Krüger, D. Jocham

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

Cross sectional comparisons of GAPDH and β-actin gene expression.

Supplementary Figure S2

FLAG β-actin p53 SET M.w. kDa D β-actin p53 G9a

Marissa V. Powers, Paul A. Clarke, Paul Workman Cancer Cell

Apoptosis-targeted therapies for cancer

Supplementary Figure 2. Effect of IL-32 and siRNA of IL-32 on melanoma, colon and prostate cancer cell growth and apoptosis as well as IL-32 expression.

Molecular Therapy - Nucleic Acids

Volume 3, Issue 4, Pages (April 2003)

Supplementary Figure 1 HCT116 MOLT4

A B C D eIF3e shRNA 205 clones Control shRNA 3 7 eIF3e b-actin

mRNA level as % relative to

Supplementary Figure S1

Supplementary Figure S4

Fold Change of hsa-miR-3687 (T/N)(log2)

Supplementary Fig. S1 BCL2 5’flanking ctrl siRNA luc

Volume 26, Issue 2, Pages (August 2014)

Apoptosis-targeted therapies for cancer

Supplementary Figure 1 A B C SW620 HT29 SW620

USP2a overexpression modifies the microRNA expression profile of prostate cells. USP2a overexpression modifies the microRNA expression profile of prostate.

Supplementary Figure S1

Supplemental Figure 1 Cell proliferation (% of mock)

Polyamine concentration (nmol/mg protein)

Molecular Therapy - Nucleic Acids

Variation in dUTPase expression in cell lines.

BORIS mRNA expression in DNMT deficient HCT116 cell lines.

Supplementary Figure S5

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

Distribution of FGFR aberrancies in urothelial cancers.

Supplementary Figure 3. ICOS expression on Tfh and Tfr cells in the peripheral blood has negative or weak correlations with serum IL-21 levels and autoantibody.

Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3 S284 through MDM2. Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

mRNA expression of PARP1 in SCLC cell lines and solid tumors.

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti- androgen Receptor Therapy in Prostate Cancer Cells Xiaowei Zhang, Daniela.

Volume 3, Issue 4, Pages (April 2003)

Presentation transcript:

Supplementary Figure S1: FGFR4 silencing synergistically enhances the effects of chemotherapy in colon cancer cells. siFGFR4 FGFR4_6 FGFR4_2 Neg Con FGFR4 βActin A B C D

Supplementary Figure S2: FGFR4 silencing decreasesSTAT3 activity and mRNA expression of FLIP and Bcl-2 siFGFR4 FGFR4_6 FGFR4_2 Neg Con pSTAT3 tSTAT3 Actin B A pSTAT3 GAPDH BGJ398 (µM) Con 5 2.5 10 24Hr tSTAT3 48Hr C

Supplementary Figure S3 FGFR4 silencing in drug resistant colon cancer cell lines. Con 5-FU OXA FUR HCT116 SN38 SNR OXR Actin FGFR4